加载中
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
常规交易时段
US$1.71
−US$0.03 · -1.72%
盘中时间采用ET。市场数据可能有所延迟。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日内区间
当前US$1.71
52周区间
当前US$1.71
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
41
合理估值
情绪
58
多空交织
风险
66
高风险
动量
17
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
日内区间
当前US$1.71
52周区间
当前US$1.71
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 681.9万 USD | 376.8万 USD | 323.2万 USD | 24.2万 USD | 24.9万 USD |
| 销售、一般及管理费用 | 515.8万 USD | 446.7万 USD | 815.5万 USD | 199.7万 USD | 81.3万 USD |
| 营业费用 | 1197.7万 USD | 823.5万 USD | 1138.7万 USD | 223.9万 USD | 106.2万 USD |
| 利息收入 | 2.1万 USD | 2.5万 USD | — | — | — |
| 利息支出 | — | — | 208.2万 USD | 65.3万 USD | 54.7万 USD |
| 折旧和摊销 | 4000 USD | 4000 USD | 4000 USD | 3000 USD | 7.3万 USD |
| 营业利润 | −1197.7万 USD | −823.5万 USD | −1138.7万 USD | −223.9万 USD | −106.2万 USD |
| 净利润 | −1195.6万 USD | −820.7万 USD | −1303.7万 USD | −321.7万 USD | −155.9万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年1月26日 | 1:28 | — | — |
股票拆分 | 2025年2月24日 | 1:17 | — | — |
股票拆分 | 2024年6月18日 | 1:13 | — | — |
股票拆分 | 2024年1月30日 | 1:7 | — | — |
股票拆分 | 2023年4月24日 | 1:30 | — | — |
已生效 2026年1月26日
1:28
已生效 2025年2月24日
1:17
已生效 2024年6月18日
1:13
已生效 2024年1月30日
1:7
已生效 2023年4月24日
1:30
报告持有此股票敞口的交易所交易基金。
State Street SPDR Dow Jones Global Real Estate ETFRWO104.33万0.09%11.83亿 USD0.50%US$46.555+0.59%
State Street SPDR Dow Jones International Real Estate ETFRWX80.88万0.34%2.39亿 USD0.59%US$25.105-0.44%
State Street SPDR S&P International Small Cap ETFGWX33万0.04%9.08亿 USD0.40%US$45.27-0.64%
State Street SPDR Portfolio Europe ETFSPEU5.96万0.01%6.83亿 USD0.07%US$53.065-0.12%
Vanguard Extended Market ETFVXF4.1万0.00%954亿 USD0.05%US$233.96-0.44%State Street SPDR Dow Jones Global Real Estate ETFRWOState Street SPDR Dow Jones International Real Estate ETFRWXState Street SPDR S&P International Small Cap ETFGWXState Street SPDR Portfolio Europe ETFSPEUVanguard Extended Market ETFVXFAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
